切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2024, Vol. 13 ›› Issue (02) : 163 -168. doi: 10.3877/cma.j.issn.2095-3232.2024.02.008

临床研究

血小板和淋巴细胞比值联合CA19-9在胆囊癌术后患者预后评估中的价值
马振威1, 朱博1, 刘赋斌1, 邓正栋2, 王剑明3,†()   
  1. 1. 430064　武汉科技大学附属天佑医院肝胆胰外科
    2. 430030　武汉，华中科技大学同济医学院附属同济医院小儿外科
    3. 430064　武汉科技大学附属天佑医院肝胆胰外科；430030　武汉，华中科技大学同济医学院附属同济医院胆胰外科
  • 收稿日期:2023-12-26 出版日期:2024-04-10
  • 通信作者: 王剑明
  • 基金资助:
    国家自然科学基金(81874062，82072730)

Evaluation value of platelet-to-lymphocyte ratio combined with CA19-9 for postoperative prognosis of patients with gallbladder cancer

Zhenwei Ma1, Bo Zhu1, Fubin Liu1, Zhengdong Deng2, Jianming Wang3,†()   

  1. 1. Department of Hepatobiliary and Pancreatic Surgery, Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan 430064, China
    2. Department of Pediatric Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
    3. Department of Hepatobiliary and Pancreatic Surgery, Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan 430064, China; Department of Hepatobiliary and Pancreatic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
  • Received:2023-12-26 Published:2024-04-10
  • Corresponding author: Jianming Wang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

马振威, 朱博, 刘赋斌, 邓正栋, 王剑明. 血小板和淋巴细胞比值联合CA19-9在胆囊癌术后患者预后评估中的价值[J]. 中华肝脏外科手术学电子杂志, 2024, 13(02): 163-168.

Zhenwei Ma, Bo Zhu, Fubin Liu, Zhengdong Deng, Jianming Wang. Evaluation value of platelet-to-lymphocyte ratio combined with CA19-9 for postoperative prognosis of patients with gallbladder cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(02): 163-168.

目的

探讨术前血小板和淋巴细胞比值（PLR）联合CA19-9在胆囊癌患者术后预后评估中的价值。

方法

回顾性分析2015年12月至2020年12月华中科技大学同济医学院附属同济医院收治的67例胆囊癌术后患者临床资料。其中男28例，女39例；平均年龄（58±10）岁。患者均签署知情同意书，符合医学伦理学规定。生存分析采用Kaplan-Meier法和Log-rank检验；Cox多因素回归分析影响胆囊癌患者术后预后的独立危险因素；采用ROC曲线下面积（AUC）分析PLR +CA19-9预测胆囊癌患者术后预后的能力。

结果

PLR、CA19-9、PLR + CA19-9对胆囊癌患者术后3年总体生存期（OS）预测的ROC曲线分析显示，最佳界值分别为162、38、0.65。Cox多因素回归分析显示，PLR≥162和CA19-9≥38 kU/L是胆囊癌患者术后预后的独立危险因素（HR=3.093，3.852；P<0.05）。低水平和高水平PLR + CA19-9组中位OS分别为43、15个月，差异有统计学意义（χ2=44.342，P<0.05）。PLR预测胆囊癌患者术后1、3年无进展生存期的AUC分别为0.741、0.777，CA19-9相应为0.838、0.780，PLR + CA19-9相应为0.901、0.882。

结论

术前PLR联合CA19-9在胆囊癌患者术后预后评估中的预测价值大于PLR或CA19-9单独评估，有一定的临床应用价值。

关键词: 胆囊癌, 血小板, 淋巴细胞, 血小板和淋巴细胞比值（PLR）, CA19-9, 预后
Objective

To evaluate the value of preoperative platelet-to-lymphocyte ratio (PLR) combined with CA19-9 in evaluating postoperative prognosis of patients with gallbladder cancer.

Methods

Clinical data of 67 patients with gallbladder cancer admitted to Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology from December 2015 to December 2020 were retrospectively analyzed. Among them, 28 patients were male and 39 female, aged (58±10) years on average. The informed consents of all patients were obtained and the local ethical committee approval was received. Survival analysis was performed by Kaplan-Meier method and Log-rank test. The independent risk factors of postoperative prognosis of patients with gallbladder cancer were identified by multivariate Cox regression analysis. The efficiency of PLR + CA19-9 for predicting postoperative prognosis of patients with gallbladder cancer was assessed by delineating the area under ROC curve (AUC).

Results

ROC curve analysis showed that the optimal thresholds of PLR, CA19-9 and PLR + CA19-9 for predicting 3-year overall survival (OS) of patients with gallbladder cancer were 162, 38 and 0.65, respectively. Multivariate Cox regression analysis indicated that PLR≥162 and CA19-9≥38 kU/L were the independent risk factors for postoperative prognosis of patients with gallbladder cancer (HR=3.093, 3.852; P<0.05). The median OS in the low and high PLR + CA19-9 groups was 43 and 15 months, and the difference was statistically significant (χ2=44.342, P<0.05). The AUC of PLR in predicting postoperative 1- and 3-year progression-free survival of patients with gallbladder cancer was 0.741 and 0.777, 0.838 and 0.780 for CA19-9, and 0.901 and 0.882 for PLR + CA19-9, respectively.

Conclusions

Preoperative PLR combined with CA19-9 has higher value in predicting postoperative prognosis of patients with gallbladder cancer compared with PLR or CA19-9alone, which is of certain value in clinical application.

Key words: Gallbladder cancer, Platelet, Lymphocytes, Platelet-lymphocyte ratio (PLR), CA19-9, Prognosis
表1 PLR和CA19-9对胆囊癌术后患者3年OS预测的ROC曲线分析
影响因素 约登指数 最佳界值 敏感度 特异度 AUC 95%CI P值
PLR 0.537 162 0.537 1.000 0.777 0.645～0.908 0.008
CA19-9 0.619 38 0.619 1.000 0.780 0.654～0.907 0.029
PLR + CA19-9 0.722 0.65 0.822 0.899 0.906 0.819～0.992 0.004
图1 PLR、CA19-9对胆囊癌患者术后3年OS预测的ROC曲线注：PLR为血小板和淋巴细胞比值，AUC为曲线下面积，OS为总体生存期
表2 PLR+CA19-9与胆囊癌术后患者临床病理指标的相关性
影响因素 类别 PLR + CA19-9 χ2值 P值
低水平组 高水平组
Plt（×109/L） ≥247/<247 6/24 23/14 11.997 0.001
淋巴细胞（×109/L） ≥1.7/<1.7 18/12 9/28 8.764 0.003
PLR ≥162/<162 0/30 27/10 36.669 0.001
CA19-9（kU/L） ≥38/<38 5/25 28/9 23.080 0.001
胆固醇（mmol/L） ≥3.4/<3.4 26/4 19/18 9.369 0.002
ALT（U/L） ≥48/<48 5/25 18/19 7.517 0.006
AST（U/L） ≥40/<40 4/26 14/23 5.063 0.024
AFP（μg/L） ≥2.7/<2.7 17/13 20/17 0.046 0.831
CEA（μg/L） ≥1.47/<1.47 23/7 30/7 0.195 0.659
WBC（×109/L） ≥8/<8 3/27 11/26 3.902 0.048
性别 男/女 15/15 24/13 1.505 0.220
年龄（岁） ≥60/<60 15/15 21/16 0.304 0.581
AJCC分期 Ⅰ/Ⅱ/Ⅲ 18/5/7 18/14/5 3.908 0.142
肿瘤分化 低/中/高 14/12/6 6/20/9 5.585 0.067
表3 影响胆囊癌患者术后预后的单因素分析
影响因素 类别 例数 中位生存期（月） χ2值 P值
淋巴细胞(×109/L) ≥1.7/<1.7 27/40 35/17 13.397 0.001
PLR ≥162/<162 27/40 15/33 24.202 0.001
CA19-9 (kU/L) ≥38/<38 33/34 15/32 20.620 0.001
AFP (μg/L) ≥2.7/<2.7 37/30 25/24 7.012 0.008
表4 影响胆囊癌患者术后预后的Cox多因素回归分析
影响因素 b SE(b) Wald χ2 HR 95%CI P值
AFP<2.71 μg/L -0.300 0.297 1.021 0.741 0.414～1.325 0.312
淋巴细胞<1.70×109/L -0.314 0.385 0.665 0.730 0.343～1.554 0.415
PLR≥162 1.129 0.379 8.867 3.093 1.471～6.504 0.003
CA19-9≥38 kU/L 1.348 0.331 16.608 3.852 2.014～7.367 0.001
图2 不同PLR + CA19-9水平胆囊癌患者术后总体生存的Kaplan-Meier曲线注：PLR为血小板和淋巴细胞比值
图3 PLR、CA19-9及PLR + CA19-9预测胆囊癌患者术后1、3年PFS的ROC曲线注：PLR为血小板和淋巴细胞比值，PFS为无瘤生存期
[1]
Misra S, Chaturvedi A, Misra NC, et al. Carcinoma of the gallbladder[J]. Lancet Oncol, 2003, 4(3):167-176.
[2]
钱昌林, 刘颖斌. TNM分期在胆囊癌根治性切除术中地位和作用[J]. 中国实用外科杂志, 2022, 42(9):1046-1050.
[3]
Zhao F, Yang D, He J, et al. Establishment and validation of a prognostic nomogram for extrahepatic cholangiocarcinoma[J]. Front Oncol, 2022(12):1007538.
[4]
李静静, 刘卫, 曲强, 等. 胆囊癌患者151例新版TNM分期的临床评估[J]. 中华肝胆外科杂志, 2014, 20(7):507-510.
[5]
Chen W, Wang S, Zhao H, et al. High level of tumor marker CA19-9returned to normal after cholecystectomy in calculous cholecystitis patients[J]. Scand J Gastroenterol, 2023, 58(6):643-648.
[6]
陈达, 樊艳华. CA19-9在胰腺癌中的应用价值及局限性[J]. 临床肝胆病杂志, 2013, 29(3):239-241.
[7]
Acevedo-León D, Gómez-Abril Sá, Sanz-García P, et al. The role of oxidative stress, tumor and inflammatory markers in colorectal cancer patients: a one-year follow-up study[J]. Redox Biol, 2023(62):102662.
[8]
Nøst TH, Alcala K, Urbarova I, et al. Systemic inflammation markers and cancer incidence in the UK Biobank[J]. Eur J Epidemiol, 2021, 36(8):841-848.
[9]
Singh J, Shukla D, Gupta S, et al. Clinical epidemiology of gallbladder cancer in North-Central India and association of immunological markers, NLR, MLR and PLR in the diagnostic/prognostic prediction of GBC[J]. Cancer Treat Res Commun, 2021(28):100431.
[10]
Rawla P, Sunkara T, Thandra KC, et al. Epidemiology of gallbladder cancer[J]. Clin Exp Hepatol, 2019, 5(2):93-102.
[11]
杨自逸, 刘诗蕾, 蔡晨, 等. 胆囊癌临床诊疗的新进展[J]. 中华外科杂志, 2022, 60(8):784-791.
[12]
Roa J C, García P, Kapoor VK, et al. Publisher correction: gallbladder cancer[J]. Nat Rev Dis Primers, 2022, 8(1):75.
13]
Hakura A, Sui H, Seki Y, et al. DNA polymerase κ suppresses inflammation and inflammation-induced mutagenesis and carcinogenic potential in the colon of mice[J]. Genes Environ, 2023, 45(1):15.
[14]
Gong Y, Pang H, Yu Z, et al. Construction of inflammatory associated risk gene prognostic model of NSCLC and its correlation with chemotherapy sensitivity[J]. Ann Med, 2023, 55(1):2200034.
[15]
Best MG, Sol N, Kooi I, et al. RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics[J]. Cancer Cell, 2015, 28(5):666-676.
[16]
Fang T, Yin X, Wang Y, et al. Lymphocyte subset is more suitable than systemic inflammatory response biomarker and immunoglobulin in constructing prognostic nomogram model for advanced gastric cancer[J]. Heliyon, 2023, 9(3):e14669.
[17]
Xiao Z, Wang X, Chen X, et al. Prognostic role of preoperative inflammatory markers in postoperative patients with colorectal cancer[J]. Front Oncol, 2023(13):1064343.
[18]
Zhu S, Yang J, Cui X, et al. Preoperative platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as predictors of clinical outcome in patients with gallbladder cancer[J]. Sci Rep, 2019, 9(1):1823.
[19]
Pang Q, Zhang LQ, Wang RT, et al. Platelet to lymphocyte ratio as a novel prognostic tool for gallbladder carcinoma[J]. World J Gastroenterol, 2015, 21(21):6675-6683.
[20]
Luo G, Jin K, Deng S, et al. Roles of CA19-9 in pancreatic cancer: biomarker, predictor and promoter[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(2):188409.
[21]
Wang YF, Feng FL, Zhao XH, et al. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer[J]. World J Gastroenterol, 2014, 20(14):4085-4092.
[22]
何丽琳, 沈永祥. 四项肿瘤标志物联合测定对胆囊癌患者预后的影响[J]. 检验医学与临床, 2018, 15(7):1014-1017.
[23]
Hao C, Sui Y, Li J, et al. The clinical value of the combined detection of enhanced CT, MRI, CEA, and CA199 in the diagnosis of rectal cancer[J]. J Oncol, 2021: 8585371.
[24]
Huang J, Ren K. Detection of changes in CEA and ProGRP levels in BALF of patients with peripheral lung cancer and the relationship with CT signs[J]. Contrast Media Mol Imaging, 2023: 1421709.
[25]
Zhang J, Qin SD, Li Y, et al. Prognostic significance of combined α-fetoprotein and CA19-9 for hepatocellular carcinoma after hepatectomy[J]. World J Surg Oncol, 2022, 20(1):346.
[26]
Zhao Q, Dong L, Liang H, et al. Evaluation of multiple biological indicators for combined diagnosis of gastric cancer: a retrospective analysis[J]. Medicine, 2022, 101(47):e31904.
[1] 薛雨柔, 孔洁, 朱龙玉, 韩慧娜, 张钧, 刘志坤. 局部治疗在乳腺癌术后孤立性局部区域复发中的作用[J]. 中华乳腺病杂志(电子版), 2024, 18(01): 18-24.
[2] 刘政宏, 王凤力, 吉亚君, 高佳. 胃癌中ELK3蛋白的表达与临床病理特征和预后的关系研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 155-159.
[3] 张琳, 李婷. CRIP1在胃癌中的表达及与临床病理指标和预后的关系研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 171-175.
[4] 朱显钟, 李金雨, 于忠英, 温路生. 淋巴结平均直径与无淋巴结转移肾癌病理特征及预后关系研究[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(02): 146-151.
[5] 王振, 黄璐, 郎连群, 岳麓. 血小板和白蛋白/纤维蛋白原比值在晚期非小细胞肺癌贝伐珠单抗二线治疗的临床意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(01): 35-40.
[6] 王婷, 余江. 1 820例罕见病的临床特征分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(01): 68-72.
[7] 王礼光, 严庆, 廖珊, 符荣党, 陈焕伟. 微血管侵犯及手术切缘对肝细胞癌患者术后生存预后的影响[J]. 中华肝脏外科手术学电子杂志, 2024, 13(02): 151-157.
[8] 苏日顺, 卢逸, 庄宝鼎, 张译, 李彦杰, 徐见亮. 肝硬化脾亢脾切除术后门静脉血栓形成影响因素[J]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 39-44.
[9] 黄金灿, 王迪, 崔松平, 陈晴, 吕少诚, 贺强, 郎韧. 预后营养指数对交界可切除胰腺癌患者术后预后的预测价值[J]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 51-56.
[10] 赵海清, 张威, 李琴. 肌苷联合免疫检查点抑制剂在转移性结直肠癌患者中的临床疗效观察[J]. 中华结直肠疾病电子杂志, 2024, 13(01): 54-62.
[11] 朱琴琴, 慈娟娟, 崔璐, 许海蓉, 李宇新, 丁炎波. 凝血功能、血脂、C反应蛋白及中性粒细胞/淋巴细胞水平对克罗恩病活动性评估及临床诊断的价值[J]. 中华消化病与影像杂志(电子版), 2024, 14(01): 35-40.
[12] 谢鸿, 李娜, 李尚日, 谢涛. 肠道菌群特征对结肠癌化学治疗疗效的影响[J]. 中华消化病与影像杂志(电子版), 2024, 14(01): 53-56.
[13] 孟丽君, 宋芹, 邵莉, 李健. 系统性红斑狼疮合并肺动脉高压患者外周血T淋巴细胞亚群水平变化及临床意义[J]. 中华诊断学电子杂志, 2024, 12(01): 38-43.
[14] 计超, 向群. 乙酰胆碱受体对急性呼吸窘迫综合征小鼠T细胞亚群和炎症因子的影响[J]. 中华诊断学电子杂志, 2024, 12(01): 50-56.
[15] 吕泉龙, 史文杰, 孙文国. 免疫检查点抑制剂在治疗转移性去势抵抗性前列腺癌中的研究进展[J]. 中华诊断学电子杂志, 2024, 12(01): 69-72.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号